Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (374)	2/4/1999 9:26:00 AM
From: LLCF	Respond to of 613

You know this SHMN is offered at .09/shr Any takers?? don't they have anything left? DAK BTW, MTSL lowered their buy price to $1.

To: Arthur Radley who wrote (374)	2/4/1999 11:54:00 AM
From: Steve Lokness	Read Replies (1) \| Respond to of 613

I would pay the 150 bucks! There are two fields here as I see it; diagnostics which would test the individual to see what the "spelling" is and the second use of pharmacogenomics helps make drug testing for FDA approval a success. The collapse of CLPA (assuming no fraud) because of their recent unblinding, might have been prevented if the company understood who was benefiting and who was not - IOW which patients had the right "spelling" for their drug. Cost here is not much of a concern obviously as the companies market cap spirals down. This I think is where GLGC hopes to capitalize. Back to diagnostics or the reading of an individuals "spelling". This is being done now, for instance in the testing of HER2. The treatment prescribed will depend on the outcome of this test. Mike, the testing to find out the patients HER2 status could be a COST SAVINGS for health care givers as only the patients who benefit from expensive treatment will be given the treatment. Two different businesses really using the same science and each with huge potential! MHO of course. Steve